We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Name | Symbol | Market | Type |
|---|---|---|---|
| Merck KGaA (PK) | USOTC:MKKGY | OTCMarkets | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.08 | 0.21% | 37.35 | 36.95 | 37.87 | 37.5355 | 37.2745 | 37.52 | 21,346 | 21:30:43 |
From Jun 2023 to Jun 2024
By David Sachs
Merck KGaA said that it has partnered with BenevolentAI and Exscientia on an initiative to discover more drugs with artificial intelligence, which the company says will yield higher success rates.
The German science and technology company said on Wednesday that the partnership with the two U.K. AI firms includes access to an AI platform to generate new drug candidates in oncology, cancer, neurology and immunology. BenevolentAI and Exscientia will each receive upfront payments for their work in the low double-digit millions and will be eligible for additional payments depending on net sales.
The deal includes three potential drug targets with the possibility of more in the future, Merck said. Financial details were not disclosed.
Write to David Sachs at david.sachs@wsj.com
(END) Dow Jones Newswires
September 20, 2023 01:50 ET (05:50 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Merck KGaA (PK) Chart |
1 Month Merck KGaA (PK) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
